Takahashi N, Kunii Y, Kanno H, Kikuchi K
Gan To Kagaku Ryoho. 1982 Sep;9(9):1640-5.
The levels of anticancer drugs in tissue were measured by bioassay method in 28 patients with gastrointestinal cancer, who were treated with intravenous administration of 500 mg of 5-FU combined with ANG-II during surgery. The levels of 5-FU in the cancerous tissue of the stomach and the regional lymph nodes were higher in the cases who received 5-FU and ANG-II than in the cases received 5-FU alone. Based on this result, we carried out cancer chemotherapy combined with ANG-II for 15 patients with advanced cancer. The good clinical response was observed in 4 out of 15 cases (26.7%) including 2 complete (CR) and 2 partial responses (PR), respectively. According to Karnofsky's criteria of response, more than I-A response was observed in 5 out of 15 cases (33.3%). The major side effects of ANG-II therapy were nausea, vomiting and breast pain. The incidence of the side effects was 8.7% in total.
采用生物测定法对28例胃肠道癌患者组织中的抗癌药物水平进行了测定，这些患者在手术期间接受了500毫克5-氟尿嘧啶与血管紧张素II联合静脉给药治疗。接受5-氟尿嘧啶和血管紧张素II治疗的患者，其胃癌组织和区域淋巴结中5-氟尿嘧啶的水平高于仅接受5-氟尿嘧啶治疗的患者。基于这一结果，我们对15例晚期癌症患者进行了联合血管紧张素II的癌症化疗。15例患者中有4例（26.7%）观察到良好的临床反应，分别包括2例完全缓解（CR）和2例部分缓解（PR）。根据卡诺夫斯基反应标准，15例患者中有5例（33.3%）观察到超过I-A级反应。血管紧张素II治疗的主要副作用为恶心、呕吐和胸痛。副作用总发生率为8.7%。
Zotero 插件